207 related articles for article (PubMed ID: 32246177)
1. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
[TBL] [Abstract][Full Text] [Related]
2. MRI-Defined Corpus Callosal Atrophy in Multiple Sclerosis: A Comparison of Volumetric Measurements, Corpus Callosum Area and Index.
Granberg T; Bergendal G; Shams S; Aspelin P; Kristoffersen-Wiberg M; Fredrikson S; Martola J
J Neuroimaging; 2015; 25(6):996-1001. PubMed ID: 25786805
[TBL] [Abstract][Full Text] [Related]
3. MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis.
Platten M; Martola J; Fink K; Ouellette R; Piehl F; Granberg T
J Neuroimaging; 2020 Mar; 30(2):198-204. PubMed ID: 31750599
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Simon JH; Jacobs LD; Campion MK; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Miller DE; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE; Brownscheidle CM
Neurology; 1999 Jul; 53(1):139-48. PubMed ID: 10408550
[TBL] [Abstract][Full Text] [Related]
5. Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis.
Platten M; Brusini I; Andersson O; Ouellette R; Piehl F; Wang C; Granberg T
J Neuroimaging; 2021 May; 31(3):493-500. PubMed ID: 33587820
[TBL] [Abstract][Full Text] [Related]
6. Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Granberg T; Martola J; Bergendal G; Shams S; Damangir S; Aspelin P; Fredrikson S; Kristoffersen-Wiberg M
Mult Scler; 2015 Aug; 21(9):1151-8. PubMed ID: 25480866
[TBL] [Abstract][Full Text] [Related]
7. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
[TBL] [Abstract][Full Text] [Related]
8. Corpus callosum index correlates with brain volumetry and disability in multiple sclerosis patients.
Sugijono SE; Mulyadi R; Firdausia S; Prihartono J; Estiasari R
Neurosciences (Riyadh); 2020 Jul; 25(3):193-199. PubMed ID: 32683399
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
10. Central Atrophy Early in Multiple Sclerosis: Third Ventricle Volumetry versus Planimetry.
Lutz T; Bellenberg B; Schneider R; Weiler F; Köster O; Lukas C
J Neuroimaging; 2017 May; 27(3):348-354. PubMed ID: 27897360
[TBL] [Abstract][Full Text] [Related]
11. Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis.
Klawiter EC; Ceccarelli A; Arora A; Jackson J; Bakshi S; Kim G; Miller J; Tauhid S; von Gizycki C; Bakshi R; Neema M
J Neuroimaging; 2015; 25(1):62-7. PubMed ID: 24816394
[TBL] [Abstract][Full Text] [Related]
12. 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis.
Pontillo G; Cocozza S; Di Stasi M; Carotenuto A; Paolella C; Cipullo MB; Perillo T; Vola EA; Russo C; Masullo M; Moccia M; Lanzillo R; Tedeschi E; Elefante A; Brescia Morra V; Brunetti A; Quarantelli M; Petracca M
Eur Radiol; 2020 Jul; 30(7):3813-3822. PubMed ID: 32100089
[TBL] [Abstract][Full Text] [Related]
13. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.
Kalincik T; Vaneckova M; Tyblova M; Krasensky J; Seidl Z; Havrdova E; Horakova D
PLoS One; 2012; 7(11):e50101. PubMed ID: 23166826
[TBL] [Abstract][Full Text] [Related]
14. Developing easy to perform routine MRI measurements as potential surrogates for cognitive impairment in MS.
Morrow SA; Menon S; Rosehart H; Sharma M
Clin Neurol Neurosurg; 2017 Feb; 153():73-78. PubMed ID: 28061362
[TBL] [Abstract][Full Text] [Related]
15. Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
Fujimori J; Nakashima I
J Neuroimmunol; 2024 Feb; 387():578280. PubMed ID: 38171046
[TBL] [Abstract][Full Text] [Related]
16. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability.
Paolillo A; Pozzilli C; Gasperini C; Giugni E; Mainero C; Giuliani S; Tomassini V; Millefiorini E; Bastianello S
J Neurol Sci; 2000 Mar; 174(2):85-91. PubMed ID: 10727693
[TBL] [Abstract][Full Text] [Related]
17. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging.
Simon JH; Schiffer RB; Rudick RA; Herndon RM
AJNR Am J Neuroradiol; 1987; 8(4):599-604. PubMed ID: 3113196
[TBL] [Abstract][Full Text] [Related]
18. Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study.
Odenthal C; Simpson S; Oughton J; van der Mei I; Rose S; Fripp J; Lucas R; Taylor B; Dear K; Ponsonby AL; Coulthard A;
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):453-460. PubMed ID: 27995735
[TBL] [Abstract][Full Text] [Related]
19. Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status.
Papathanasiou A; Messinis L; Zampakis P; Papathanasopoulos P
J Clin Neurosci; 2017 Sep; 43():170-175. PubMed ID: 28601572
[TBL] [Abstract][Full Text] [Related]
20. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.
Vidal-Jordana A; Sastre-Garriga J; Pérez-Miralles F; Pareto D; Rio J; Auger C; Tintoré M; Rovira A; Montalban X
J Neuroimaging; 2016 Sep; 26(5):532-8. PubMed ID: 26935253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
